Dr. Pep

Peptides · GHRH analogue

Tesamorelin: what the studies show

Every line below comes from a study, label or regulator record, checked by two models, with the source linked. Information, not medical advice. For adults 18+.

What it is

  • Tesamorelin is a lab-made version of growth-hormone-releasing hormone (GHRH 1-44). It makes the pituitary gland release the body's own growth hormone. It is injected under the skin once a day.[1][2]
  • It is the FDA-approved prescription drug Egrifta. Two products exist, Egrifta SV and Egrifta WR, which have different strengths and doses and are not substitutable. It is not the same as sermorelin or CJC-1295.[2][3]

Bottom line

  • Tesamorelin is an approved drug for one purpose: reducing excess belly fat in adults with HIV-related lipodystrophy. Large trials show it cuts deep belly fat by about 15% but it is not a weight-loss drug, it raises IGF-1, and it should not be used with active cancer or in pregnancy. Evidence for other uses is small.[4][1][2]

What the human studies found

  • HIV with belly fat, first phase 3 trial (double-blind RCT, 412 adults with HIV and excess abdominal fat, 2 mg daily for 26 weeks): visceral fat fell 15.2% on tesamorelin and rose 5.0% on placebo. Triglycerides fell 50 mg/dL versus a 9 mg/dL rise. IGF-I rose 81%.[4]
  • Pooled analysis of the two phase 3 trials (806 adults, 543 on tesamorelin 2 mg, 263 on placebo, 26 weeks plus a 26-week extension): visceral fat fell 24 cm2 versus a rise of 2 cm2 on placebo, a treatment effect of -15.4%. Subcutaneous fat did not change significantly.[1]
  • A 2026 meta-analysis of five RCTs in HIV: visceral fat fell by 27.7 cm2, liver fat by 4.3 percentage points and trunk fat by 1.2 kg, while lean mass rose 1.4 kg. BMI and subcutaneous fat did not fall significantly.[5]
  • Fatty liver in HIV (double-blind RCT, 61 people, 2 mg daily for 12 months): liver fat fell by 4.1 percentage points more than on placebo (a 37% relative fall).[6]
  • Memory and thinking, not an approved use (double-blind RCT, 152 adults aged 55 to 87, 66 with mild cognitive impairment, 1 mg daily for 20 weeks): thinking scores improved versus placebo (p=0.03), driven by executive function. IGF-1 rose 117% and body fat fell 7.4%.[7]

Known risks and side effects

  • Label warnings: higher risk of tumours (preexisting malignancy must be inactive and treated first, and treatment should stop if cancer returns); raised IGF-1, which should be monitored; fluid retention, including swelling, joint pain and carpal tunnel syndrome; glucose intolerance or diabetes; hypersensitivity reactions; and higher death risk in people with acute critical illness. There is no boxed warning on the Egrifta SV label. Long-term cardiovascular safety has not been established.[2]
  • In the label's 26-week trials (543 on tesamorelin, 263 on placebo), injection-site reactions were 17% versus 6%, joint pain 13% versus 11%, muscle pain 6% versus 2%, peripheral swelling 6% versus 2%, and numbness or tingling 5% versus 2%.[2]

Legal status

  • FDA approved: Egrifta SV and Egrifta WR (labels dated 2026) for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The label states it is not indicated for weight loss.[2][3]
  • FDA warning letters dated 2026-08-24 to Peptide Partners LLC and NuScience Peptides LLC cited tesamorelin among research-use-only or unapproved peptide products, and a 2020-04-01 letter to Tailor Made Compounding LLC listed tesamorelin among its compounded products.[8][9][10]

Sources

  1. [1] Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
  2. [2] Egrifta Sv (Tesamorelin) Kit prescribing information
  3. [3] Egrifta Wr (Tesamorelin) Kit prescribing information
  4. [4] Metabolic effects of a growth hormone-releasing factor in patients with HIV.
  5. [5] Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
  6. [6] Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
  7. [7] Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.
  8. [8] FDA: Warning Letter, Peptide Partners LLC (2026-08-24), research-use-only semaglutide, tirzepatide, retatrutide, tesamorelin, PT-141
  9. [9] FDA: Warning Letter, NuScience Peptides LLC (2026-08-24), tesamorelin, ipamorelin, PT-141, retatrutide, survodutide, mazdutide
  10. [10] FDA: Warning Letter, Tailor Made Compounding LLC (2020-04-01), BPC-157, CJC-1295, ipamorelin, GHK-Cu, semax, selank, epitalon, DSIP, LL-37, PT-141, melanotan, MK-677, tesamorelin